Summary of Use during Lactation

No information is available on the clinical use of brentuximab during breastfeeding. Because brentuximab is a large protein molecule with a molecular weight of about 153,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, brentuximab vedotin should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be discontinued during brentuximab therapy.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Name

Brentuximab Vedotin

CAS Registry Number

914088-09-8

Drug Class

Breast Feeding

Lactation

Antibodies, Monoclonal